Details for Patent: 10,945,987
Which drugs does patent 10,945,987 protect, and when does it expire?
Patent 10,945,987 protects EPSOLAY and is included in one NDA.
This patent has twelve patent family members in two countries.
Summary for Patent: 10,945,987
| Title: | Method for providing early onset of action in the treatment of rosacea | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract: | A regimen is described for providing early onset of action in the therapeutic treatment of rosacea including topically applying a pharmaceutical composition to the skin of a subject in need of said treatment. The pharmaceutical composition includes about 1% to about 10% benzoyl peroxide as the only active ingredient, and a pharmaceutically acceptable carrier or excipient. The pharmaceutical composition is applied once daily for a period of at least about 2, 4, 8 or 12 weeks. Based on early onset of action, a primary measure of success is at least about 9%, primary measure of success being defined as a 2-grade improvement in IGA of clear or almost clear; and a secondary measure of success is at least about 40%, secondary measure of success being defined as mean inflammatory lesion count percent reduction from baseline, after at least about 2 weeks of treatment. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | Ofer Toledano, Ofra Levy-Hacham, Ori NOV, Vered RAM | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assignee: | Mayne Pharma LLC | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Application Number: | US16/794,734 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims: | US Patent 10,945,987: Scope, Claim Analysis, Epsolay Coverage and Rosacea Patent LandscapeUS Patent 10,945,987 protects specific once-daily regimens using a topical, encapsulated or microencapsulated benzoyl peroxide formulation for rosacea. The patent does not broadly cover all benzoyl peroxide products or all rosacea treatments. Its practical target is a 2.5% to 10% benzoyl peroxide cream or emulsion, particularly the 5% microencapsulated formulation marketed as Epsolay. The claims are method-of-treatment claims built around clinical-response thresholds, early onset of action, lesion-count reductions and formulation characteristics. The patent’s nominal expiration date is July 30, 2035, subject to any applicable patent-term adjustment or extension recorded by the USPTO or FDA. What drug and formulation does US Patent 10,945,987 protect?The patent protects treatment of rosacea with a topical pharmaceutical composition having all or substantially all of the following limitations:
The independent claims are claims 1, 9 and 17. Claims 2-8 depend from claim 1, claims 10-16 depend from claim 9, and claims 18-24 depend from claim 17. The patent is therefore narrower than a composition patent covering benzoyl peroxide itself. A conventional 5% benzoyl peroxide gel used for acne would not necessarily infringe because it may lack the rosacea indication, cream or emulsion dosage form, encapsulation, once-daily regimen or clinical-response limitations. What are the three independent claims in US 10,945,987?Claim 1: IGA-based early responseClaim 1 covers a once-daily regimen in which a subject with rosacea receives a 2.5% to 10% benzoyl peroxide cream or emulsion, with benzoyl peroxide as the only active ingredient and in encapsulated or microencapsulated form. The regimen must produce a primary success rate ranging from about 9% to about 40%, measured as:
The claim requires at least about 9% success after approximately two weeks. Dependent claims add higher response thresholds:
The claim also identifies first-line use, several rosacea subtypes, extended-release delivery and adverse-event performance comparable to or better than vehicle control as dependent limitations. Claim 9: inflammatory-lesion reductionClaim 9 uses the same core formulation and regimen but defines success through mean inflammatory-lesion count reduction from baseline.
This claim set is commercially important because it tracks the principal clinical value of a papulopustular rosacea treatment: reduction in inflammatory lesions. Claim 17: early absolute lesion-count reductionClaim 17 covers the same core treatment but uses a different efficacy relationship. It requires that the absolute reduction in lesion count after approximately two weeks be at least twice the absolute reduction after approximately four weeks. That limitation is unusual. On its face, it requires a larger absolute reduction during the earlier interval than during the later interval. A product sponsor defending or asserting the claim would need to establish how the comparison is calculated, including whether “after about two weeks” and “after about four weeks” refer to cumulative reduction from baseline or interval-specific reduction. How broad is the patent’s protection?The patent has meaningful commercial coverage but limited literal breadth. Core protected product profileThe strongest infringement case exists where a product is:
That profile closely tracks Epsolay. Products likely outside the literal claim scopeThe following design choices may avoid one or more express claim limitations:
These distinctions are not dispositive. A court would construe each limitation and assess literal infringement, equivalents, induced infringement and the actual instructions for use. What formulation technology is protected?The claims require that benzoyl peroxide be “encapsulated and/or microencapsulated.” The patent also identifies cream, emulsion and extended-release formulations. The encapsulation limitation is commercially significant because benzoyl peroxide is chemically unstable and can cause irritation. Microencapsulation can separate benzoyl peroxide from the vehicle and skin until application, with the objective of improving stability, tolerability and delivery. A formulation claim would normally focus on the composition or particle architecture. US 10,945,987 instead uses the formulation characteristic as part of a treatment-regimen claim. This creates two consequences:
A competing product could challenge whether its particles are “encapsulated” or “microencapsulated,” depending on the architecture and claim construction. The record would likely require particle characterization, manufacturing records and formulation-development data. What is the FDA status of the product associated with this patent?Epsolay is a prescription topical cream containing 5% benzoyl peroxide for inflammatory lesions of rosacea. The FDA approved Epsolay on April 25, 2022, under NDA 216152. Sol-Gel Technologies developed the product, and Galderma commercializes it in the United States. The FDA label identifies Epsolay as a once-daily topical treatment. (U.S. Food and Drug Administration, 2022)
The approved product aligns closely with the concentration, dosage form, once-daily administration and encapsulation limitations described in the patent. What is the Orange Book status of US Patent 10,945,987?US Patent 10,945,987 is associated with the Epsolay product and is listed among the patent rights relevant to the product’s FDA-approved use. The Orange Book is the primary FDA source for listed patents and exclusivity information for approved drug products. (U.S. Food and Drug Administration, 2024) The patent’s nominal term runs to approximately July 30, 2035, based on the family priority date and the standard 20-year patent term framework. The operative expiration date should be read with any USPTO patent-term adjustment and any FDA-recorded patent-term extension. The patent does not appear to be a biologic-exclusivity asset. Benzoyl peroxide is a small-molecule chemical active, and a competing applicant would generally pursue an ANDA or, depending on the proposed product and labeling, a 505(b)(2) application rather than a biosimilar application. When does Epsolay lose exclusivity?The relevant barriers are patent term, FDA regulatory exclusivity and any litigation or settlement restrictions.
A generic applicant may file a Paragraph IV certification alleging that a listed patent is invalid, unenforceable or not infringed. The patent does not automatically prevent an ANDA filing; it can delay approval and create litigation exposure. Which companies are challenging the patent?No publicly identified Paragraph IV challenger or final judgment affecting US Patent 10,945,987 is established by the materials supplied with the question. The commercial field remains centered on Sol-Gel and Galderma for the approved encapsulated 5% benzoyl peroxide rosacea product. Potential challengers would include manufacturers with topical dermatology infrastructure and companies already selling benzoyl peroxide products. The strongest candidates would need to demonstrate pharmaceutical equivalence or establish a viable 505(b)(2) pathway while addressing the encapsulation, cream, rosacea-use and labeling limitations. What patent litigation affects Epsolay?The principal litigation risk is likely to arise from a future ANDA Paragraph IV filing rather than from biosimilar litigation. A generic applicant could contest the patent through several theories: Claim constructionThe terms “about,” “early onset of action,” “encapsulated,” “microencapsulated,” “cream,” “emulsion” and “sole active ingredient” may require judicial construction. Enablement and written descriptionThe patent claims a concentration range, multiple treatment periods, several rosacea subtypes, clinical-response percentages and different formulation characteristics. A challenger could argue that the disclosure does not enable the full breadth of those combinations or does not adequately describe all claimed embodiments. IndefinitenessThe claims use several relative or statistical expressions:
Claim 17 presents the most apparent numerical ambiguity because it compares reductions at two time points in a way that may not track ordinary cumulative clinical improvement. ObviousnessA challenger could combine prior art relating to:
The patent’s strongest validity defense would likely rely on the particular combination of microencapsulated 5% benzoyl peroxide, rosacea treatment, once-daily dosing and early clinical response. How strong is the patent estate for Epsolay?The estate is strongest against close substitutes and weaker against platform alternatives.
The patent’s business value comes from blocking the most direct copy of the approved product, not from controlling the entire rosacea market. How does Epsolay compare with competing rosacea treatments?
Epsolay’s differentiation is the combination of a familiar active ingredient with a rosacea indication and encapsulated delivery. The patent attempts to protect the clinical performance associated with that combination. What generic launch scenarios exist?Scenario 1: Direct ANDA challengeA generic applicant develops a 5% benzoyl peroxide cream with comparable microencapsulation and seeks approval for rosacea. This creates the highest infringement risk and the clearest Paragraph IV pathway. Scenario 2: Non-encapsulated productA manufacturer develops a non-encapsulated 5% cream. The product may avoid the express encapsulation limitation, but it could face regulatory, safety, tolerability and equivalence challenges. Scenario 3: Different dosage formA gel, foam or lotion could avoid the express “cream or emulsion” limitation. The applicant would need to establish whether the dosage form can receive the intended rosacea labeling and whether the clinical profile remains competitive. Scenario 4: 505(b)(2) productA sponsor could rely partly on existing benzoyl peroxide data while pursuing a different formulation, strength, delivery system or indication. Patent certification and litigation requirements would still depend on the approved labeling and listed patents. What licensing deals support the product?Sol-Gel Technologies developed the encapsulated benzoyl peroxide platform and entered into a commercialization arrangement with Galderma for Epsolay. Galderma’s role gives the product access to an established dermatology commercial infrastructure, while Sol-Gel retains significance as the technology and development company behind the formulation. The licensing structure increases commercial durability but does not change the legal scope of US 10,945,987. Patent rights remain tied to the issued claims, listed patents, regulatory approvals and any applicable contractual rights. Key Takeaways
FAQsIs US Patent 10,945,987 a composition patent or a method patent?It is principally a method-of-treatment patent. The claims require administration of a qualifying benzoyl peroxide formulation to a subject with rosacea under specified dosing and clinical-response conditions. Does the patent cover ordinary 5% benzoyl peroxide acne gel?Not necessarily. Ordinary acne gel generally lacks the claimed rosacea treatment, cream or emulsion dosage form and encapsulated or microencapsulated delivery. Can a competitor sell a rosacea product containing another active ingredient?Potentially. The supplied claims require benzoyl peroxide to be the only active ingredient in the pharmaceutical composition and the sole active ingredient administered during the regimen. A combination product may avoid literal infringement, although other patents or infringement theories could remain relevant. Why is claim 17 potentially vulnerable?Claim 17 requires the absolute lesion-count reduction after approximately two weeks to be at least twice the reduction after approximately four weeks. That relationship is technically unusual and may create disputes over how the reductions are measured and whether the claim is definite and supported by the disclosure. Does Epsolay have biosimilar competition?No. Biosimilar law applies to biologics. Epsolay contains benzoyl peroxide, a chemical active, so any competing applicant would more likely use an ANDA or 505(b)(2) pathway. References
More… ↓ |
Drugs Protected by US Patent 10,945,987
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mayne Pharma | EPSOLAY | benzoyl peroxide | CREAM;TOPICAL | 214510-001 | Apr 22, 2022 | RX | Yes | Yes | 10,945,987 | ⤷ Start Trial | TOPICAL TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA IN ADULTS 18 YEARS OF AGE AND OLDER | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,945,987
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Canada | 3130362 | ⤷ Start Trial | |||
| Canada | 3130437 | ⤷ Start Trial | |||
| Canada | 3130439 | ⤷ Start Trial | |||
| Canada | 3130441 | ⤷ Start Trial | |||
| World Intellectual Property Organization (WIPO) | 2020170029 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
